Segregation of mitochondrial DNA heteroplasmy through a developmental genetic bottleneck in human embryos by Floros VI et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Floros VI, Pyle A, Dietmann S, Wei W, Tang WWC, Irie N, Payne B, Capalbo A, 
Noli L, Coxhead J, Hudson G, Crosier M, Strahl H, Khalaf Y, Saitou M, Ilic D, 
Surani MA, Chinnery PF.  
Segregation of mitochondrial DNA heteroplasmy through a developmental 
genetic bottleneck in human embryos.  
Nature Cell Biology 2018, 20, 144-151. 
 
 
Copyright: 
This is the authors’ accepted manuscript of an article that was published in its final definitive form by 
Nature, 2018. 
DOI link to article: 
https://doi.org/10.1038/s41556-017-0017-8  
Date deposited:   
22/02/2018 
Embargo release date: 
15 July 2018  
 1 
NCB-C33065-R3 
Segregation of mitochondrial DNA heteroplasmy through a 
development genetic bottleneck in human embryos   
Vasileios I. Floros*,1,2 Angela Pyle*,3 Sabine Dietmann,4 Wei Wei,1,2  Walfred W.C. Tang,5 
Naoko Irie,5 Brendan Payne,4 Antonio Capalbo,6,7 Laila Noli,8,9 Jonathan Coxhead,4 Gavin 
Hudson,4 Moira Crosier,10 Henrik Strahl,11 Yacoub Khalaf,8,9 Mitinori Saitou,12,13 Dusko 
Ilic,8,9 M. Azim Surani,5 Patrick F. Chinnery.1,2¶ 
1MRC-Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, UK. 
2Department of Clinical Neurosciences, Cambridge Biomedical Campus, University of 
Cambridge, Cambridge, CB2 0QQ, UK. 3Wellcome Trust Centre for Mitochondrial Research, 
Institute of Genetic Medicine, Central Parkway, Newcastle University, Newcastle upon Tyne, 
NE1 3BZ, UK. 4Wellcome Trust-Medical Research Council Stem Cell Institute, Tennis Court 
Road, University of Cambridge, Cambridge CB2 3EG, UK. 5Wellcome Trust Cancer 
Research UK Gurdon Institute, Tennis Court Road, University of Cambridge, Cambridge, 
CB2 3EG, UK. 6GENERA, Centre for Reproductive Medicine, Clinica Valle Giulia, 00197 
Rome, Italy. 7GENETYX, Reproductive Genetics Laboratory, Via Fermi 1, 36063 Marostica, 
Italy. 8Division of Women’s Health, Faculty of Life Sciences and Medicine, King's College 
London, London SE1 7EH, UK. 9Assisted Conception Unit, 11th Floor Tower Wing, Guy’s 
Hospital, Great Maze Pond, London SE1 9RT, UK. 10Human Developmental Biology 
Resource, Institute of Genetic Medicine, Central Parkway, Newcastle University, Newcastle 
upon Tyne, NE1 3BZ, UK. 11Centre for Bacterial Cell Biology, Institute for Cell and 
Molecular Biosciences, Baddiley-Clark Building, Richardson Road, Newcastle University, 
Newcastle upon Tyne, NE2 4AX, UK. 12Department of Anatomy and Cell Biology, Graduate 
School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, 
Japan. 13JST, ERATO, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 
 2 
 
*equal contribution 
¶ Correspondence to: pfc25@cam.ac.uk 
 3 
Mitochondrial DNA (mtDNA) mutations cause inherited diseases and are implicated in 
the pathogenesis of common late-onset disorders, but how they arise is not clear1,2. Here 
we show mtDNA mutations are present in primordial germ cells (PGCs) within healthy 
female human embryos. Isolated PGCs which have a profound reduction in mtDNA 
content, with discrete mitochondria containing ~5 mtDNA molecules.  Single cell deep 
mtDNA sequencing of in vivo human female PGCs showed rare variants reaching 
higher heteroplasmy levels in late PGCs, consistent with the observed genetic 
bottleneck. We also saw the signature of selection against non-synonymous protein-
coding, tRNA gene and D-loop variants, concomitant with a progressive upregulation of 
genes involving mtDNA replication and transcription, and linked to a transition from 
glycolytic to oxidative metabolism. The associated metabolic shift would expose 
deleterious mutations to selection during early germ cell development, preventing the 
relentless accumulation of mtDNA mutations in the human population predicted by 
Muller’s ratchet. Mutations escaping this mechanism will show shifts in heteroplasmy 
levels within one human generation, explaining the extreme phenotypic variation seen 
in human pedigrees with inherited mtDNA disorders.   
 
The 16.5 Kb human mitochondrial genome (mtDNA) encodes 37 genes essential for the 
synthesis of 13 polypeptide subunits of the respiratory chain, the final common pathway of 
oxidative metabolism1. In humans, mtDNA is inherited exclusively down the maternal line.  
Diploid cells typically contain 1-10,000 mtDNA molecules partitioned between a network of 
fusing and budding mitochondria. Exposed to a potent source of oxygen free radicals and 
lacking protective histone proteins, mtDNA is particularly vulnerable to mutation, creating a 
mixed population of wild-type and mutated mtDNA within a cell (heteroplasmy)2. MtDNA 
mutations accumulate in in non-dividing (post mitotic) cells during life, with high levels 
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observed in late onset human disorders including Alzheimer’s disease and Parkinson’s 
disease. Although the overall tissue mutation burden is low, very high levels within single 
cells lead to bioenergetic failure and ultimately cause cell death1. These findings raise the 
possibility that mtDNA mutations contribute to the pathogenesis of several common human 
diseases, and also play a part in the ageing process itself3, but the origin of these mutations 
has not been unclear.   
 
Age-associated mtDNA mutations were assumed to have arisen in somatic tissues during life, 
but deep sequencing of maternal relatives raises the possibility that low-level mtDNA 
heteroplasmic point mutations are inherited down the maternal line4. To determine whether 
this is the case, we developed methods to isolate pure primordial germ cells (PGCs) from first 
trimester karyotypically normal human female embryos (Fig.1). Anatomical regions 
containing migrating PGCs were dissected from fresh 4-week embryos, and genital ridges 
were isolated from 5-8 week embryos. Single cell suspensions were then labelled with 
fluorochrome-conjugated antibodies against putative human germ cell surface markers, and 
sorted using fluorescence-activated cell sorting (FACS). Tissue non-specific alkaline 
phosphatase (TNAP) histochemistry5, VASA immunocytochemistry6 (Supplementary 
Fig.1), and germ-cell specific transcripts (Supplementary Figs.1&2)7, were used to 
determine the proportion of PGCs after FACS sorting at appropriate developmental stages. 
Highly purified (>97%) PGCs were isolated in 4 week (Carnegie stage, CS12) embryos using 
a combination of TNAP, stage-specific embryonic antigen 4 (SSEA4) and the PGC-
associated cell-surface marker CD38; and for weeks 5-8 (CS16/17 – CS20/21) we used 
TNAP and c-KIT antibodies (Fig.1b).  
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After cell lysis, mtDNA was amplified in overlapping 2Kb fragments to minimise potential 
contamination from nuclear-encoded mitochondrial insertions (NumtS), before >5000-fold 
depth re-sequencing. NumtS contamination was further minimized by filtering-out all 
variants with a minor allele frequency (MAF) <1%. Sequencing of a cloned mtDNA template 
showed no variants present at 1% MAF (Supplementary Fig.3). However, we observed 
mtDNA single nucleotide variants (SNVs) at >1% heteroplasmy in PGCs isolated from all 12 
embryos studied (Fig.2a), which did not map to known human NumtS8. This shows that low-
level mtDNA heteroplasmy is present within the female germ line in healthy humans. The 
variants were predominantly nucleotide transitions, which are less prone to in vitro 
sequencing error and less likely to be due to oxidative damage9, and are consistent with errors 
during in vivo DNA synthesis by mtDNA polymerase ϒ or the deamination of cytidine and 
adenosine10.  
 
We also observed a change in the mutation spectrum from CS12 to CS20/21 (Fig.2a). For 
protein coding genes, there was a decrease in the proportion of non-synonymous variants 
(non-synonymous/synonymous ratio, P=0.02) and a corresponding change in the codon bias 
(Fig.2b&c). We also saw a decrease in the mutation rate / base pair for tRNA genes (Fig.2d), 
which are hallmarks of selection against potentially deleterious mtDNA variants. Similar 
patterns have been seen in mice11,12, but the timing and mechanism of the selection was not 
known. Based on our observations, this occurs at an early stage in the developing human 
female germ line during PGC specification and migration. We were surprised to see some 
evidence of selection against variants in the non-coding mtDNA D-loop (Fig.2d), but these 
did not appear to be evenly distributed. CS12 PGCs contained variants in conserved regions 
not present in CS20/21 PGCs (Fig.2e), consistent with selection against variants in regions 
involved in mtDNA transcription and replication13.  
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Given that the majority of the mtDNA variants were present at low heteroplasmy levels 
(Fig.2a), below the conventional threshold required for a biochemical effect, it was not 
immediately apparent how the selection could occur. To explore the potential mechanism, we 
measured the absolute amount of mtDNA in the human PGCs at different stages of 
development in vivo, and then sequenced individual late-stage PGCs to look for evidence of 
variant segregation. First we studied human oocytes from three healthy donors, which 
contained a mean of 1.22 x106 mtDNA molecules (SD=189,742, n=3)14. This was in keeping 
with previous measurements15 and confirmed assay reliability. The amount of mtDNA in 
human PGCs from 14 embryos in vivo was ~1000-fold less than in oocytes (CS12 mtDNA 
copies: median 1425, mean 1446, SD=77) (Fig.2f), consistent with a human genetic 
bottleneck. The mtDNA levels in female and male PGCs were similar, as previously seen in 
mice16, and resembled new measurements made in Blimp1-mVenus and Stella-eCFP [BVSC] 
mice17 (Fig.2f, Mouse E9.5 corresponds to human CS12; and mouse E12.5 corresponds to 
human CS20/21). This validates previous findings in mice with different nuclear genetic 
backgrounds16,18,19, and shows a similar mechanism in both humans and mice. However, the 
lower amount of mtDNA we observed in human PGCs (human/mouse: CS12/E9.5, 
P<0.0001; CS16-7/E10.5, P<0.0001; CS20-21/E12.5, P<0.0001) predicts a ‘tighter’ genetic 
bottleneck in humans than in mice, and thus the more rapid segregation of heteroplasmy. This 
is in accordance with observations in human and mouse pedigrees where more dramatic shifts 
in heteroplasmy are seen in humans (see Fig.4a in Ref20). 
 
It is not technically possible to isolate human PGCs from earlier stages because the cells are 
collected from clinical samples. However, to gain further insight we also measured mtDNA 
levels in single cells from both the human inner cell mass (ICM) and trophectoderm (TE) 
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cells (Fig.2g). Although we saw a wide range of mtDNA levels in ICM cells, the mean level 
(9794, SD=5661) was >5-fold greater than in PGCs. We then studied embryonic stem cells 
(hESCs) and human PGC-like cells (hPGCLCs)7,21 which are derived from the embryonic 
epiblast in vitro, thus allowing us to estimate the amount of mtDNA at an intermediate stage 
of human germ cell development (Fig.2h). hESCs (mean=3264, SD=378) contained less 
mtDNA than ICM cells, and hPGCLCs (mean=896, SD=368) contained less mtDNA than 
hESCs (P=8.9x10-33). These findings are in keeping with a post implantation mtDNA 
bottleneck. The female hPGCLCs (mean=533, SD=203) contained significantly less mtDNA 
than male hPGCLCs (mean=991, SD=342, P=1.5x10-5), and less mtDNA than both male 
(mean=1102, SD=426, P=2.2x10-16) and female (mean=972, SD=248, P=2.2x10-16) somatic 
cells isolated from the same in vitro system but not expressing germ-cell markers. These 
findings suggest a more stringent mtDNA bottleneck in the human female germ line.  
 
Returning to the PGCs isolated in vivo, next we analysed the sub-cellular distribution of 
mtDNA molecules within the developing human female germ line. We used the dissector 
method to measure the number of mitochondria in human PGCs on adjacent section electron 
micrographs (EM) (Fig.3a), validating our results with super-resolution whole cell imaging 
using Nikon Structured Illumination Microscopy in 3-dimensions (N-SIM, Supplementary 
Movies 1 & 2, Fig.3b). The number of mitochondria did not change between CS12 and 
CS20-21, allowing us, to estimate the number of mtDNA per mitochondrion at ~5 per 
organelle in human PGCs. The reduction in mtDNA content after fertilization of the oocyte 
(Fig.2f), and associated intracellular compartmentalisation of mtDNA (Figs.3a&b), has 
important implications for the distribution of mtDNA heteroplasmy between individual 
organelles. Assuming that mutated mtDNA molecules are randomly distributed between 
mitochondria, higher levels of heteroplasmy within a cell will be associated with a greater 
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proportion of mitochondria containing very high levels (>80%) of a specific mutation 
(Fig.3c).  For example, if the average level within a cell is 40-50% mutant, then 10-20% of 
the organelles will contain >80% mutant mtDNA, exceeding the threshold required to cause a 
biochemical defect for pathogenic mutations1,2. In this context, ~10-20% of the organelles 
would be dysfunctional and potentially vulnerable to removal by mitochondrial quality 
control mechanisms, removing mutated mtDNA through selection at the organellar level. To 
determine whether this is plausible, we performed deep mtDNA sequencing on individual 
late-stage in vivo PGCs (Fig.3d&e). This showed much higher percentage levels of mtDNA 
heteroplasmy within individual germ cells, reaching up to 47% mutant. Thus, following the 
bottleneck, high levels of mtDNA mutations are found in single PGCs, and are predicted to 
reach very high levels in individual mitochondria (Fig.3c). The most likely explanation for 
the observed change in codon bias seen between CS12 and CS20-21 (Fig.2b), in the is the 
rapid segregation of variants above and below the assay detection threshold (1% MAF) due 
to the genetic bottleneck (Fig.2a&c), rather than de novo mutation events per se. In this 
context, even a subtle bias against deleterious variants would tend to suppress them below the 
detection threshold, whilst allowing non-functional variants to segregate freely to high levels 
(Fig.3d).  
 
To cast light on the possible mechanism of selection, we performed RNA-seq on weeks 4-9 
human PGCs. Unsupervised hierarchical clustering (UHC) of gene expression and principal 
component analysis (PCA) of transcriptome confirmed strong expression of germ-cell 
specific transcripts (Fig.4a-c). Importantly, we also observed a distinct transcript profile for 
the nuclear-encoded mitochondrial proteins (MitoCarta2.0)22 in the early stages of PGC 
development (Fig.4d). Principal component analysis (PCA) of both the nuclear-encoded and 
the mtDNA-encoded transcripts showed that the most dramatic changes were during the early 
 9 
stages of germ cell development, with mitochondrial genes forming a cluster distinct from 
late gonadal PGC genes, such as DAZL and DDX4 (Supplementary Fig.4). The mtDNA-
encoded transcripts had the highest scores on PC1, accounting for 92% of the total variance 
(Fig.4e). This is consistent with the developmental progression of mtDNA gene expression 
during PGC development. In contrast, genes involved in the canonical glycolysis pathway 
had opposing trends on PC1 (Supplementary Fig.4&5). Although based solely on transcript 
analysis, these findings suggest that PGCs become less dependent on glycolytic metabolism 
and more dependent on oxidative metabolism as they develop. As a consequence, non-
synonymous mtDNA mutations are progressively more likely to have phenotypic 
consequences during germ cell development. The proliferation of PGCs between CS12 and 
CS20/21 requires considerable mtDNA replication, inevitably introducing new mutations 
through ϒ polymerase errors. These new mutations are more likely to be synonymous (Fig.2) 
and have no functional consequence. The switch from glycolytic to oxidative metabolism 
provides an explanation for these findings, by exposing functional variants to the selective 
effects during this critical time period of PGC development.   
 
Germ-line mtDNA selection at the organelle level has been proposed in mammals12,23 and 
Drosophila24,25, but it is not known how this occurs. One possibility is that mitochondria 
depolarise when the proportion of mutated respiratory chain subunits is high, activating 
intracellular surveillance systems mediated by Pink1 and Parkin, and leading to the selective 
removal of damaged organelles containing mutant mtDNA by mitophagy26,27. Alternatively, 
impaired mtDNA replication in ATP-deficient organelles28 could leading to the preferential 
turnover of mitochondria containing wild-type genomes; or the transport of mitochondria 
may be compromised in deficient organelles, preventing their coalescence around the 
Balbiani body where intense mtDNA replication occurs18. In our data, specific genes that 
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were upregulated >2.5-fold (Fig.4f) included POLRMT, C10orf2, SLC25A4, and MRPL28, 
which play a key role in mtDNA replication and gene expression (Supplementary Table 4), 
similarly seen in the PCA (Supplementary Fig.4). Thus, mtDNA variants influencing 
mtDNA replication and expression will also be more likely to have an effect as PGCs 
develop, providing a possible explanation for the signature of selection we observed against 
tRNA and D-loop variants between CS12 and CS21 (Figs.2d&e).  
 
We also saw low levels of mtDNA somatic cells in vitro (Fig.2h) and in vivo (Fig.5a), in 
keeping with a somatic cell bottleneck, as previously observed in mice19. We also detected 
mtDNA variants in the somatic cells in vivo at similar levels to PGCs (Fig.5b), but the 
segregation pattern appeared to be different. Some of the mtDNA variants were detected in 
both the PGCs and the somatic cells from the same embryo, but by the later stages (n=15 
shared variants, CS16-17 & CS20-21), the somatic cells contained higher heteroplasmy levels 
(P 0.034, Fig.5c). Although based on limited data, this suggests that a less stringent mtDNA 
bottleneck is present in somatic cells within human embryos, and that mtDNA variants are 
less constrained by selection in somatic tissues than in the germ line.  
 
With rudimentary DNA repair mechanisms and negligible intermolecular recombination, 
uniparentally inherited genomes have limited means of removing de novo mutations. If left 
unchecked, the relentless accumulation of mtDNA mutations would eventually lead to 
‘mutational meltdown’ through Muller’s ratchet, and extinction of the species29. The mtDNA 
genetic bottleneck has probably evolved to counteract this process, exposing potentially 
deleterious mutations to selective forces. Based on our findings, in humans this occurs early 
during germ-line development (Fig.5d). However, if a mutation is sufficiently mild to escape 
germ-line selection, the same genetic bottleneck can have disastrous consequences. First 
 11 
observed in Holstein cows30, dramatic shifts in heteroplasmy levels have been observed 
within one generation. In humans, healthy mothers harbouring a low level heteroplasmic 
mtDNA mutation can have offspring with high levels of heteroplasmy and a severe 
multisystem disease. Pedigree analyses are consistent with a human mtDNA bottleneck31, but 
there has been no direct evidence in humans. Here we show that a human mtDNA genetic 
bottleneck exists, and is narrower than the bottleneck in mice16,18 (Fig.2f). Reducing the 
amount of mtDNA during this critical time of germ cell development will expose variants to 
selection acting at either the cellular, organellar or mtDNA level, because this coincides with 
germ cells expressing transcripts for oxidative phorphorylation as they proliferate and 
migrate to form the gonad. Harnessing the underlying cell biology could help prevent human 
mtDNA disease which currently affect ~1 in 11,000. Moreover, given the potential role of 
mtDNA mutations in common age-related disorders32, preventing their transmission may 
have a wider impact by promoting healthy ageing in future generations.  
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Figure 1. Isolation of a pure population of human primordial germ cells (PGCs).  
(a) Human and mouse developmental time points used in this study. Upper panel - Prdm1 
(Blimp1)-mVenus and Dppa3 (Stella)-eCFP [BVSC] mouse embryos (E9.5 and E10.5) and 
gonads (E12.5) 17. Arrows show the fluorescent mouse PGCs subsequently isolated by 
fluorescent sorting. Upper panel scale bars from left to right: 0.5 mm, 1 mm, 0.5 mm. Lower 
panel – fresh human female embryos showing lower core-body dissected area (red line 
drawing) for 4 Wk (Carnegie stages, CS, 12) embryos (left), and dissected female embryonic 
gonads for 5.5 - 6 Wk (CS16/17) and 8 Wk (CS20/21) embryos (middle & right) Lower panel 
scale bar = 1 mm.  
(b) Isolation of human PGCs by fluorescent sorting using: for week 4 (CS12) dissected 
embryos - a triple positive combination for TNAP, stage-specific embryonic antigen 4 
(SSEA4) and CD38, and for weeks 5-8 (CS16/17 – CS20/21) gonadal tissue double positive 
for TNAP and c-KIT. Boxes in the FACS plots show the sorted cell population. 
(c) Purity of isolated hPGCs was validated by alkaline phosphatase activity-staining showing 
>97% positive cells. Scale bar = 100 µm. 
See also Fig.4a-c and Supplementary Figs. 1&2. Observations for b & c were independently 
replicated three times at each developmental stage.  
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Figure 2. Mitochondrial DNA variants in human primordial germ cells.  
(a-e) Mitochondrial DNA (mtDNA) variants exceeding the assay detection threshold (minor 
allele frequency, MAF) of >1% during human primordial germ cell (PGC) development. 
Carnegie stage, CS12 = blue, CS16/17 = red, CS20/21 = orange. Data were derived from 
n=80 single cells sorted from two CS12 embryos, n=240 cells sorted from four CS16/17 
embryos, and n=360 cells sorted from six CS20/21 embryos.  
(a) Frequency distribution of mtDNA variants at sequential stages of germ line development.  
(b) Codon positions affected by the coding region mutations (No codon bias for CS12, P = 
NS, significant codon bias for CS20/21, P = 0.005, Fisher’s exact text, 2-sided).  
(c) Proportion of non-synonymous (shaded) variants and synonymous (open) (dN/dS, P = 
0.02, Fisher’s exact text, 2-sided). 
(d) Evidence of selection against mtDNA variants in tRNA genes (P=0.03, Fisher’s exact 
text, 2-sided) and the non-coding Displacement (D)-loop (P = 0.003) between CS12 and 
CS20/21.  
(e) Position of the variants detected in the non-coding mtDNA D-loop region. 
(f) MtDNA content of single in vivo PGCs from human (left, n = 117) and Blimp1-
mVenus and Stella-eCFP [BVSC] mouse (right, n = 68) embryos. Each data point represents 
the mtDNA content in a single cell corresponding to the mean value from the independent 
qPCR measurements. Source data available in Supplementary Table 6. 
(g) MtDNA content of single human inner cell mass (ICM, n = 20), trophectoderm (TE, n 
= 12) cells from five embryos in vivo. Each data point represents the mtDNA content in a 
single cell corresponding to the mean value from the independent qPCR measurements. 
Source data available in Supplementary Table 6. 
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(h) MtDNA content of single human embryonic stem cells (hESCs, n = 18), somatic cells 
(n = 30), and human primordial germ-cell like cells (hPGCLC, n = 48) isolated in vitro7,21. 
Two independent PGCLC inductions were performed for both the male (WIS2) and female 
(H9) ESC lines, with cells analysed at day 5/6. Source data available in Supplementary Table 
6. Each data point represents the mtDNA content in a single cell corresponding to the mean 
value from the independent qPCR measurements. Horizontal lines in (f-h) represent the mean 
values.  
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Figure 3. Morphology and deep sequencing of single human primordial germ cells in 
vivo.    
(a) Upper, N-SIM image of a human PGC labelled with anti-TOM20 (Supplementary 
movie 1) with mitochondria identified and counted by IMARIS (Supplementary movie 2). 
Scale bar = 2 µm. Lower, transmission electron micrographs (TEM) characteristic of human 
PGCs33. White fat arrow = nucleolus; white thin arrow = chromatin, electron dense glycogen 
particles, and lipid droplets; pink arrow = pseudopodia in the migratory stage (CS12) PGCs 
(right image). Round discrete mitochondria around the nucleus (orange arrows). Scale bar = 2 
µm. Similar observations made from three independent experiments. 
(b) Number of mitochondria in human primordial germ cells. Left (EM, n=24 cells): 
mitochondrial count per cell using the dissector method and serial section EMs. Right (N-
SIM, n=12 cells):  super-resolution microscopy. Each data point represents a measurement 
from a single PGC. EM: mean=275.9, median=272, SD 87.76. N-SIM: mean=288.8, 
median=272, SD=72.12. The horizontal bar represents the mean value. 
(c) Probability of an individual mitochondrion containing mutated mtDNA molecules as a 
function of the overall heteroplasmy level within the cell. Binomial distributions assuming 5 
molecules/mitochondrion that are randomly distributed between organelles. For cells 
containing 40-50% mutant mtDNA, many mitochondria are likely to contain 4 or more 
mutated molecules (>80%). If deleterious these high levels will potentially depolarise the cell 
triggering mitophagy, or inhibit mtDNA replication within that organelle, potentially leading 
to selection against mutations at the organellar level.   
(d) Minor allele frequency (MAF) of mtDNA variants in 20 single human PGCs from three 
CS20/21 embryos detected by deep sequencing (left panel). Right panel shows the same data 
with the Y-axis scaled from 1-10% MAF. In both panels the detection threshold was set at 
MAF >1%. 
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(e) Position of the variants from single human PGCs within the mitochondrial genome (left 
panel). Right panel shows the same data with the Y-axis scaled from 1-10% MAF. In both 
panels the detection threshold was set at MAF >1%. 
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Figure 4. Transcriptome analysis of human primordial germ cells (PGCs).  
Analysis of n = 13 transcriptomes. 
(a) Unsupervised hierarchical clustering (UHC) of RNA-seq expression profiles in H9 
Embryonic stem cells (ESCs), Wk4, Wk7, and Wk9 female (F) human PGCs and Wk5.5 
male (M) hPGCs, and gonadal somatic cells (Soma) showing clustering of gene expression 
consistent with the appropriate developmental stage (see also Supplementary Fig.4). Results 
from a single analysis of the entire transcriptome data set.  
(b) Principal component analysis (PCA) of RNA-seq gene expression in hPGC samples. 
Arrow line indicates developmental progression along PC1. 
(c) Heat map showing expression of key PGC-associated transcripts (early and late) and of 
pluripotency, mesoderm, endoderm, and gonadal somatic (Soma) markers.  
(d) Correlation of transcription profiles of human PGCs of various stages for nuclear-
encoded mitochondrial transcripts predicted by MitoCarta2.0 (see Methods, Pearson’s 
correlation, two-sided) and mtDNA-encoded transcripts. Only genes with normalized reads 
counts with (log2 (normalized counts) > 2.5) were used for analysis. Expression levels were 
averaged over biological replicates. The number of biological replicates at each 
developmental stage is shown in the cluster diagram shown in Fig.4a generated from a total 
of 13 separate transcriptomes. This shows a progressive change in transcriptome profiles for 
mitochondrial genes in a sequential manner during PGC development. 
(e) Two-dimensional principal components analysis (PCA) of RNA-seq gene expression 
(PC2 against PC1) for mitochondrial nuclear-encoded and mtDNA-encoded genes 
(MitoCarta2.0) at the different stages of hPGCs (left panel), with a corresponding plot of the 
PC scores on PC2 and PC1 (right panel). Gene names are color-coded to illustrate up-
regulated expression in hPGCs-wk9 (purple), and down-regulated expression in hPGs-wk9 
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(red) when compared with hPGCs-wk4 sample (see also Fig. 4f, Supplementary Fig.4&5 and 
Supplementary Table 4). Arrow line indicates potential mitochondrial-related-transcript 
progression for each developmental stage from migratory hPGC-wk4 to gonadal hPGC-wk9. 
(f) Volcano plot showing differentially expressed genes (from MitoCarta2.0 list) between 
week 9 (n = 2 independent replicates) and week 4 (this measurement was performed once) 
hPGCs [log2(fold change)>2.5, p < 0.05, DEseq two-sided, see Methods]. See also 
Supplementary Fig.4&5 and Supplementary Table 4. 
Note that the week 9 PGCs included in the RNAseq analysis were from a slightly later 
developmental stage than CS20/21, reflecting the clinical samples that were available.  
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Figure 5. Mitochondrial DNA analysis of somatic cells in vivo & mechanisms of 
selection.   
(a) MtDNA content of single human somatic cells in vivo at the same stage as the female 
primordial germ cells (PGCs) shown in Figs.1&2 (CS12 n=36, CS16-17 n=36; CS20-21 
n=60). Each data point represents the mtDNA content in a single cell corresponding to the 
mean value from the independent qPCR measurements from 12 embryos. The horizontal bar 
represents the mean value. Source data available in Supplementary Table 6. 
(b) Mutation frequency for human female PGCs and corresponding somatic cells (soma) 
in developing human embryos (CS12-20/21) in vivo. Data derived from 12 embryos. 
(c) Segregation of the same heteroplasmic mtDNA variants detected in somatic cells and 
PGCs from the same embryo at CS16-17 & CS20-21 (n = 15 variants) in vivo. Variants in the 
somatic cells had a higher heteroplasmy level than the PGCs (P=0.03, Fisher’s exact test, 
two-sided), which was not the case at CS12. Source data available in Supplementary Table 6. 
(d) In vivo PGCs contain ~ 300 discrete mitochondria which each containing 5 mtDNA 
molecules. In vitro data suggests that the amount of mtDNA may be even lower in female 
germ cells at an earlier stage. Some of the mtDNA molecules are mutated with either neutral 
(green) or deleterious (red) mutations. Between Carnegie Stage (CS) 12 and CS 20/21 the 
number of cells increases from ~3000 to ~80,000 accompanied by a massive proliferation of 
mtDNA molecules within the migrating PGCs. As the mitochondria replicate, the mutations 
will be copied. The random segregation of mtDNA molecules during mitochondrial fission 
will generate daughter mitochondria with either high or low levels of the original mutation. If 
the mutation is deleterious, then it will be selected against. This could be because it 
compromises ATP synthesis and activates surveillance systems that remove defective 
mitochondria, or because it compromises mtDNA replication, and thus prevents that 
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particular mitochondrion from being copied. Both of these mechanisms can act in concert at 
the cellular level and at the mitochondrial level. 
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Methods 
Isolation of single cells 
Ethically approved human embryonic tissue samples were provided by the Human 
Developmental Biology Resource (HDBR), Newcastle University, UK. For CS12 embryos, 
the lower section (see Fig. 1) was dissected in PBS from intact healthy embryos from healthy 
donors. For CS16 to CS21 embryos genital ridges from individual embryos were dissected in 
PBS and the surrounding mesonephric tissue was removed. The dissected tissue was 
dissociated to single cell suspension with 350 µl in the case of CS12 and 200 and 250 µl in 
the case of CS16/7 and CS20/1 respectively of 5U/ml Liberase DL Research Grade (Roche, 
Basel, Switzerland) at 37 °C for 20-35 minutes (depending on the stage-size of the tissue). 
The dissociated sample was then washed with 750-800µl of cold Flow Cytometry Staining 
Buffer (FCSB) (R&D Systems, Minneapolis, USA) and the solution was passed through a 50 
µm cell strainer.  20µl were removed for cell count using Tali® Image Cytometer (Life 
Technologies), before the cell suspension was centrifuged at 300 x g for 5 minutes at 4°C. 
Cells were suspended in cold FCSB and incubated with 5 µl of Brilliant Violet 421-
conjugated anti-human CD38 (Biolegend, 303526, San Diego, USA), 20 µl of Alexa Fluor 
647-conjugated SSEA-4 (BD Pharmingen, 560796) and 5 µl of Alexa Fluor 488-conjugated 
anti-alkaline phosphatase (BD Pharmingen, 561495) in the case of CS12 embryonic tissue, 
and 5 µl of Brilliant Violet 421-conjugated anti-human CD117 (c-Kit) (Biolegend, 313216, 
San Diego, USA), and 5 µl of Alexa Fluor 488-conjugated anti-alkaline phosphatase (BD 
Pharmingen, 561495) in the case of CS16/7 and CS20/1 gonadal tissue for 30 min at 4°C. 
Cells were the washed with 1 ml of FCSB and centrifuged at 300 x g for 5 minutes at 4°C. 
Cells were suspended in fresh cold FACB and sorted using FACS Aria II (BD Biosciences, 
San Jose, USA). To determine the right antibody combination for isolation of pure human 
PGCs different cell populations were sorted onto Polysine™ Microscope Adhesion Slides 
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(Thermo Fisher Scientific, Inc, USA) and left to settle in a humidified chamber at room 
temperature (RT) for 20-30 min before fixed with 4% PFA for 5 min at RT. Purity for each 
sorted population was tested with alkaline phosphatase staining using Leukocyte Alkaline 
Phosphatase Kit (Sigma-Aldrich, St. Louis, USA). Greater than 97% pure samples were used 
for downstream analysis. Initially, gender was determined by PCR as described in 34 and then 
verified by karyotype analysis. Somatic cells were isolated at the same time using the same 
protocols, and inner cell mass and trophectoderm cells were manually dissected from in vitro 
fertilized human Day 6 embryos as described35. In vitro human embryonic stem cells 
(hESCs), human primordial germ cell-like cells (hPGCLCs), and somatic cells were cultured, 
induced and isolated as described previously7,21. Two independent PGCLC inductions were 
performed for both the male (WIS2) and female (H9) ESC lines. Single cells were isolated by 
FACS using the NANOS3-tdTomato knock-in reporter and the cell surface marker for tissue 
non-specific alkaline phosphatase (TNAP) in the WIS line, and TNAP/CD38 double 
positivity in the h9 line.  The somatic were isolated during the same FACS sort and were 
negative for these markers. 
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The work with the human Day 6 embryos was done under licence from the UK Human 
Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and 
also has local ethical approval (UK National Health Service Research Ethics Committee 
Reference: 06/Q0702/90). Informed consent was obtained from all subjects and the 
experiments conformed to the principles set out in the WMA Declaration of Helsinki and the 
NIH Belmont Report. No financial inducements are offered for donation. The study is 
compliant with all relevant ethical regulations regarding research involving human 
participants. 
Measuring mtDNA content 
Lysis of PGCs: PGCs collected in 96-well plates in 40 or 80 cells per well (Life 
Technologies, Paisley, UK) were lysed for 16 hours in 50 mM Tris-HCl, pH 8.5, with 0.5% 
Tween 20 and 200 ng/ml proteinase K, at 55°C, followed by heat inactivation at 95°C for 10 
minutes.  
Lysis of single PGC: PGCs collected in 96-well plates in single cell per well (Life 
Technologies, Paisley, UK) were lysed for 30 minutes in 4 µl of 50 mM Tris-HCl, pH 8.5, 
with 0.5% Tween 20 and 200 ng/ml proteinase K, at 37°C, followed by heat inactivation at 
80°C for 15 minutes.  
Quantification of mtDNA copy number: Quantitative real-time PCR (qPCR) was performed 
on a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Human 
mitochondrial DNA copy number was calculated by absolute quantification using a 
singleplex Taqman assay targeting the mitochondrial MT-ND1 gene (Supplementary Table 
1a). Mouse mitochondrial DNA copy number was calculated by absolute quantification using 
a singleplex Taqman assay targeting the mitochondrial MT-ND5 gene (Supplementary Table 
1b). Standard curves using PCR-generated templates were used for absolute quantification. 
Samples and standards were measured in triplicate. 
 4 
Somatic cells, human inner cell mass, trophectoderm, human embryonic stem cells, human 
primordial germ cell-like cells, and in vitro somatic cells: MtDNA levels were measured 
using the same protocols as the PGCs.  
Immunocytochemistry 
PGCs were sorted on Polysine™ Microscope Adhesion Slides (Thermo Fisher Scientific, Inc, 
USA) and left to settle in a humidified chamber at room temperature (RT) for 20-30 min 
before fixation with 4% PFA for 10 min at RT. Washed three times with PBS, 0.1% Tween-
20, (5 min each wash) and incubated 20 min with PBS, 0.3% Triton-X buffer, and washed 
three times with PBS, 0.1% Tween-20 (5 min each wash). Cells were subsequently blocked 
for 1hr with PBS, 2.5% BSA, 0.1% Tween-20 and 5% normal goat serum at RT followed by 
staining with DDX4 (VASA) mouse monoclonal IgG1 Antibody (Selleckchem, Houston, 
USA) diluted 1:200 in the blocking solution at 4˚C overnight. The slides were then washed 
three times with PBS, 0.1% Tween-20 (5 min each wash) and incubated with Alexa 
fluorophore conjugated secondary antibody (Molecular Probes) 1:500 diluted in PBS, 0.1% 
Tween-20 for 1 hr at room temperature in the dark, washed three times in PBS, 0.1% Tween-
20 (5 min each wash) and once in PBS for 5 min. Finally, the glass bottom dishes were 
mounted in ProLong® Gold Antifade Mountant with DAPI (Molecular Probes) and imaged 
using a Zeiss Axio Imager Z1/Apotome Microscope.  
Electron microscopy 
PGCs collected in 1.5 ml microcentrifuge tubes containing 2.5% EM rade gluteraldehyde 
(TAAB Laboratories Equipment Ltd, Aldermaston, UK) in Sorenson’s phosphate buffer 0.2 
M pH 7.4 (Electron Microscopy Sciences, Hatfield, UK) and stored at 4°C O/N. The cells 
were enrobed in low-melting point agarose (4%) to form a small block. After secondary 
fixation in 2% osmium tetroxide (Agar Scientific, Stansted, Essex, UK), the cells were 
dehydrated in graded acetone, embedded in epoxy resin (TAAB) and polymerised at 60˚C. 
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Semi-thin sections (0.5 µm) were taken from the resin block and stained with toluidine blue 
to identify the first cells. As soon as cells were found in the block, ultrathin serial sections (70 
nm) were taken and collected on copper washer grids (Gilder Grids, Grantham, Lincolnshire, 
UK). Serial sections were taken for approximately 150 µm to ensure that there would be at 
least 6 whole cells sectioned. The grids were stained with uranyl acetate and lead citrate 
(Leica UK, Milton Keynes) and viewed on a Philips CM100 TEM (FEI, Eindhoven). Cells 
that were completely sectioned were imaged from each sample and mitochondria counted 
using the disector technique 36. Pairs of images 140 nm apart were taken at several levels 
through each cell. Each pair is comprised of a ‘reference’ and ‘look-up’ section. The number 
of mitochondria that are hit by the reference section but not by the look-up section is counted. 
To increase efficiency, the roles of the reference and look-up sections can be reversed. If the 
volume of the disector is known then the number density Nv can be obtained. The volume of 
the disector equals the area of cell profile multiplied by the distance between the paired 
sections.  Multiplying number density by cell volume gives mitochondrial number.  
Super-resolution microscopy 
PGCs collected in 35 mm diameter glass bottom dishes, (Glass No 1.5, 0.170 ± 0.005 
mm, High Tolerance Coverslip) (MatTek Corporation, Ashland, USA) and left to settle in a 
humidified chamber at room temperature (RT) for 20-30 min before fixed with 4% PFA for 
10 min at RT. Dishes were washed three times with TBS (pH 7.6), 0.1% Tween-20 (5 min 
each wash) and then permeabilized for 10 min using TBS, 0.1% sodium citrate, 0.2% Triton-
X buffer, before washed three times with TBS, 0.1% Tween-20 (5 min each wash). Cells 
were subsequently blocked for 1hr with TBS, 0.3M glycine, 2.5% BSA, 5% normal goat 
serum, 0.1% Tween-20 buffer at RT followed by staining with TOM20 mouse monoclonal 
IgG2a Antibody (F-10), sc-17764 (Santa Cruz Biotechnology, Inc., Texas, USA) diluted 
1:1000 in the blocking solution at 4˚C overnight. The glass bottom dishes were then washed 
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three times with TBS, 0.1% Tween-20 (5 min each wash) and incubated with Alexa 
fluorophore conjugated secondary antibody (Molecular Probes) 1:1000 diluted in TBS, 0.1% 
Tween-20 for 1 hr at room temperature in the dark, washed three times in PBS, 0.1% Tween-
20 (5 min each wash) and once in TBS for 5 min. Finally, the glass bottom dishes were 
mounted in ProLong® Gold Antifade Mountant with DAPI (Molecular Probes) and imaged 
using a Nikon Structured Illumination Microscope (N-SIM). 
Image segmentation analysis for measuring mitochondria content 
Three-dimensional reconstruction of super-resolution z-stack images was rendered using 
NIS-Elements software (Nikon). Mitochondria content count, and visualization of PGCs was 
performed using Imaris software (Bitplane, Belfast, UK). 
Ultra-deep sequencing and variant analysis 
Details of collected samples are given in Supplementary Table 2. PGCs and somatic cells 
were sorted and lysed in 96-well plates as described above and mtDNA was amplified using 
PrimeSTAR GXL DNA polymerase (error rate=0.00108%, Takara Bio, Saint-Germain-en-
Laye, France) in nine overlapping fragments (Supplementary Table 1c) grouped cells or in 
two overlapping fragments (Supplementary Table 1d) for the single cells. The specificity of 
mtDNA amplification was assessed using DNA extracted from Rho0 cell lines previously 
shown to be devoid of mtDNA 4. There was no template amplification after >40 PCR cycles 
confirming that the primers only amplified mtDNA and not nuclear-mitochondrial sequences 
(NUMTs). No PCR products were generated with any of the primers. Amplified products 
were assessed by gel electrophoresis, against DNA+ve and DNA-ve controls. Each amplicon 
was individually purified using Agencourt AMPure XP beads (Beckman-Coulter, USA), 
quantified using a Qubit 2.0 fluorimeter (Life Technologies, Paisley, UK) and amplicons 
from the same sample were pooled. Libraries were prepared for Next Generation Sequencing 
(NGS) using the Illumina Nextera XT DNA sample preparation kit (Illumina, CA, USA), 
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pooled amplicons were ‘tagmented’, amplified, cleaned, normalised and pooled in equimolar 
concentrations for library preparation. The library was sequenced using MiSeq Reagent Kit 
v3.0 (Illumina, CA, USA) in paired-end, 250 bp reads. Post-run FASTQ files were analysed 
using an in-house developed bioinformatic pipeline. Reads were aligned to the rCRS 
(NC_012920) using BWA v0.7.4 invoking –mem 37. Aligned reads were sorted and indexed 
using Samtools v0.1.8 38 duplicate reads were removed using Picard v1.85 
(http://broadinstitute.github.io/picard/). Variant calling was performed in tandem using 
VarScan v2.3.1 39 (minimum depth=1500, supporting reads=10, base-quality (BQ)=>30, 
mapping quality (MQ)=>20 and variant threshold=1.0%). Variants were annotated using 
ANNOVAR v529 40. Heteroplasmic variants are defined as >1% minor allele frequency. Our 
previous work using this method showed that variants present at >1% heteroplasmy were 
highly likely to have been present in the original DNA sample, and unlikely to be artefact. In-
house Perl scripts were used to extract base/read quality data and coverage data. In addition, 
low quality variants, present in low complexity regions, were not included in the analysis.  
Sequencing a cloned mtDNA template with the same protocol showed minimal background 
sequencing error (Supplementary Fig.3)  
RNA-Seq Library Preparation 
PGCs were sorted into 100 µl of extraction buffer of PicoPure RNA Isolation Kit (Applied 
Biosystems) and RNA was extracted following the manufacturer’s protocol. The Ovation 
RNA-Seq System V2 (Nugen) was used for reverse transcription and amplification of total 
RNA (0.5 to 2 ng) into cDNA. Fragments of 250 bp were generated by sonication of 
amplified cDNA using the Covaris S220 Focused-ultrasonicators. Subsequently, using 
Ovation Rapid DR Multiplex System (Nugen) and 500 ng of fragmented cDNA an RNASeq 
library was prepared.  Quantification of the library was done by qPCR using KAPA Library 
Quantification Kit (Kapa Biosystems) using QuantStudio 6 Flex Real-Time PCR System 
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(Applied Biosystems). Libraries were sequenced by HiSeq 2000/2500 sequencing system 
(Illumina) with single-end 50 bp read length. Every 4 indexed libraries were multiplexed to 
one lane of a flowcell, resulting in >40 millions single end reads per sample. 
RNA-Seq Analysis 
After removal of adaptor sequence and low-quality reads, RNA-seq reads were mapped to the 
human reference genome (UCSC GRCh37/hg19) using TopHat2 v2.0.13 
(http://ccb.jhu.edu/software/tophat) guided by ENSEMBL gene models. The annotations of 
transcripts were based on Ensembl (Release 74) considering protein coding, long-noncoding 
RNA and processed transcripts. Using featureCounts the raw counts per transcripts were 
obtained. The counts for nuclear-encoded transcripts were normalized, and statistical tests for 
differential expression of transcripts were performed by using the R Bioconductor DESeq 
package (www.bioconductor.org). To account for the profound reduction in mtDNA content, 
mitochondrial transcript counts were normalized by the set of DESeq-scaling factors obtained 
for nuclear-encoded transcripts before evaluating their differential abundance. Further 
normalization of expression-normalized transcript counts was done by transcript length (per 
kB). Hierarchical clustering plots were generated with the R ‘hclust’ functions using the 
Ward’s method. Principal components were computed by singular value decomposition with 
the R ‘prcomp’ functioned on scaled DESeq-normalized expression values. Only the 80% 
most highly expressed transcripts were used for clustering and principal component analysis. 
By selecting the most equivalent time points in human PGC development, mitochondrial 
genes that were significantly differentially expressed (log2FC > 2.5 or < -2.5 and p value < 
0.05) between hPGCs (Wk 7 or 9) and hPGCs (Wk4) were compiled and highlighted in the 
plots of the principal component (PC) scores for each gene (Fig. 5e). Human mitochondrial 
related genes were adopted from MitoCarta2.0 inventory.  
Quantitative Reverse Transcription PCR (RT-qPCR) 
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Total RNA from sorted PGCs or somatic cells was extracted by PicoPure RNA Isolation Kit 
(Applied Biosystems). cDNA was synthesized and amplified using Ovation RNA-Seq 
System V2 (Nugen). RT-qPCR reactions were set up with SYBR Green JumpStart Taq 
ReadyMix (Sigma) and 200 nM of forward and reverse primers (Table S5). RT-qPCR was 
then performed on QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) at 95˚C 
for 10 minutes, 40 cycles of 95˚C for 15 seconds and 60˚C for 1 minute, followed by a melt 
curve stage. Mean threshold cycles were determined from 2-3 technical replicates. Relative 
expression levels were calculated using the comparative Ct method, by normalization to 
GAPDH and relative to CS12 human PGCs or soma (Supplementary Figs.1&2). 
Statistics and Reproducibility 
Statistical analyses were performed using parametric methods as described in the text and 
figure legends with exact P-values reported. The number of biological replicates for each 
experiment is stated in the figure legend. 
Data availability 
mtDNA-seqdata that support the findings of this study are available in the Supplementary 
Table 5 and under accession codes SAMN08022267, SAMN08022310, SAMN08022311, 
SAMN08022312, SAMN08022313, SAMN08022314, SAMN08022315, SAMN08022316, 
SAMN08022317, SAMN08022318, SAMN08022319, SAMN08022320. RNA-seq data 
generated by this study have been deposited in the Gene Expression Omnibus (GEO) under 
the accession codes of GSM2060944 (for hPGC female week 4) and GSM2060945 (for 
Somatic cells female week 4). Previously published RNA-seq data that were re-analysed here 
are available under accession codes SRX857044, SRX857046, SRX901022, SRX901024, 
SRX901025, SRX901026, SRX901027, SRX901028, SRX901029, SRX901030, and 
RX901031. Statistics source data for Figures 2f, 2g, 2h, 5a & 5c are provided in 
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Supplementary Table 6. All other data supporting the findings of this study are available from 
the corresponding author on reasonable request.  
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